Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury

NCT06438471

Status	RECRUITING
Phase	Phase 1
Sponsor	EicOsis Human Health Inc.
Enrollment	36 participants

Key Eligibility Criteria

Inclusion (4)

- Each subject must meet all of the following criteria to be enrolled in this study:
- Male and female subjects must be 18 and older.
- Subjects must be willing to provide written informed consent to participate in the study.
- Subjects must be able to provide own transportation to study site every day for the duration of the study.

Exclusion (40)

- Subjects must have completed a minimum of 6 of the 7 daily assessments for average and worst daily pain prior to final screening, using an 11-point numerical rating scale (NRS) for average daily pain intensity, and the arithmetic average daily SCI neuropathic pain score must be e4 and d9, with a standard deviation less than or equal to 1.2. Daily pain assessment screenings will be done over the phone with the study coordinator after informed consent is obtained.
- Subjects must have failed at least 2 classes of medications for their neuropathic pain due to SCI (classes may include antidepressants, antiepileptics, opioids, anti-inflammatories, topical treatments, etc.).
- Subjects must be in overall stable condition, as determined by pre-study medical history, physical examination, clinical laboratory tests, and 12 lead ECG measurements
- Subjects must have a negative screening for HIV, Hepatitis C, and Hepatitis B within 30 days of randomization.
- Subjects must have a normal hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal axes screening study.

... and 35 more (see full listing online)

Locations (1 total)

AU Medical Center, Augusta, Georgia, United States